85803-63-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-METHYLPIPERAZIN-1-YL)BENZONITRILE is used as a building block for the synthesis of pharmaceuticals due to its compatibility with various chemical reactions and its ability to contribute to the development of new drug candidates.
Used in Medicinal Chemistry Research:
MPB is used as a research chemical for exploring its interactions with serotonin and adrenergic receptors, which is crucial for understanding its potential therapeutic effects on central nervous system disorders.
Used in Drug Development for CNS Disorders:
2-(4-METHYLPIPERAZIN-1-YL)BENZONITRILE is used as a potential therapeutic agent for the treatment of central nervous system disorders such as depression, anxiety, and schizophrenia, owing to its demonstrated affinity for relevant receptors and its promising results in preclinical studies.
Used in Neuropharmacology and Neuroscience Research:
MPB is used as an important chemical probe for investigating the modulation of neuronal activity and behavior, contributing to the advancement of knowledge in neuropharmacology and neuroscience.
Used in Preclinical Studies:
2-(4-METHYLPIPERAZIN-1-YL)BENZONITRILE is used in preclinical studies to evaluate its efficacy and safety as a potential drug candidate for various central nervous system conditions, providing valuable data for further development and clinical trials.

InChI:InChI=1/C12H15N3/c1-14-6-8-15(9-7-14)12-5-3-2-4-11(12)10-13/h2-5H,6-9H2,1H3

Upstream product

• 952281-56-0 2-(4-methyl-piperazin-1-yl)-benzonitrile hydrochloride 
• 109-01-3 1-methyl-piperazine 
• 394-47-8 2-fluorobenzonitrile 

Downstream Products

• 56915-77-6 1-[2-(4-methylpiperazin-1-yl)phenyl]ethanone 
• 655256-68-1 (2-(4-methylpiperazin-1-yl)phenyl)methanamine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors

The histone deacetylases (HDACs) are able to regulate gene expression, and histone deacetylase inhibitors (HDACi) emerged as a new class of agents in the treatment of cancer as well as other human disorders such as neurodegenerative diseases. In the prese

A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS

New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH-NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or

Method of inhibiting neoplastic cells with imidazoquinazoline derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to imidazoquinazoline derivatives.

Imidazoquinazoline derivatives

PCT No. PCT/JP97/03023 Sec. 371 Date Apr. 27, 1998 Sec. 102(e) Date Apr. 27, 1998 PCT Filed Aug. 29, 1997 PCT Pub. No. WO98/08848 PCT Pub. Date Mar. 5, 1998Imidazoquinoline derivatives of the formula (wherein X may be O or S) provide selective cyclic guanosine 3',5' monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitory activity. The compounds are useful for treating or ameliorating cardiovascular disease such as thrombosis, angina pectoris, hypertension, heart failure and arterial sclerosis, as well as asthma, impotence and the like.

Synthesis and biological properties of thiophene ring analogues of mianserin.

The synthesis of two thiophene-containing analogues of mianserin, i.e., 1,2,3,4,10,13b-hexahydro-2-methylpiperazino[1,2-a]thieno[2, 3-c][1]benzazepine (2), and the corresponding [3,2-c] isomer (12) is described. The key step in the synthesis is the nucleo